Skip to main content

Abilify Global Settlement Order Released; Status to be Addressed on June 12

Abilify Global Settlement Order Released; Status to be Addressed on June 12

Abilify Global Settlement Order Released; Status to be Addressed on June 12

Introduction

U.S. District Judge M. Casey Rodgers overseeing the Abilify litigation, released a global settlement order (PDF) on May 2, which details the parameters for the mediation of all cases to take place between May 1 and September 1, 2018. This was in view of setting a framework to aid the settlement process using the bellwether approach.  

The parties have been given two weeks to define the ‘no pay’ characteristics where plaintiffs would not be eligible for compensation under the agreement, following which they will have 14 days to identify the cases that satisfy this condition within the centralized Abilify multidistrict litigation. The mediation process would initiate once these cases have been filtered out.

The next case management conference is scheduled for June 12, when the status of the global settlement process would be addressed. This news closely follows the May 1 decision when the defendants chose to settle before scheduled trial dates.

Over 800 Abilify lawsuits were centralized in October 2016, as a part of MDL No. 2734 (In Re: Abilify Compulsive Behavior Products Liability Litigation) in the U.S. District Court for the Northern District of Florida against Bristol-Myers Squibb and Otsuka Pharmaceuticals alleging that they failed to warn the consumers and the medical community about the gambling risks associated with Abilify.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Cencora Directors Settle Opioid Oversight Case for $111M

Categories: Opioids

Cencora has agreed to pay $111.3 million to settle a shareholder lawsuit accusing the company’s directors of failing to prevent the unlawful distribution of opioids

Study Finds CPAP May Harm Low-Risk Sleep Apnea Patients

A new study has cast doubt on the long-standing belief that continuous positive airway pressure (CPAP) machines significantly reduce heart…

FDA Adds New Warnings on Long-Term Opioid Risks

Categories: Opioids

Federal regulators have raised concerns that many opioid medications were approved for prolonged use without sufficient clinical evidence confirming their safety.

✍️ FREE — 2,800 Pages Legal Process Outsourcing Trial!                 
No Contract. No Risk — Full Mass Tort + LPO Access, Free!

Only 10 Firms Accepted—Offer Ends August 31!